share_log

騰盛博藥-B：截至2024年6月30日之股份發行人的證券變動月報表

BRII-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2024

HKEX ·  Jul 2 23:14
Summary by Moomoo AI
腾盛博药-B（02137.HK）於2024年7月3日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年6月30日的公司股份變動情況。報告顯示，公司的法定/註冊股本維持不變，為1,200,000,000股普通股，每股面值0.000005美元，總額6,000美元。同時，已發行股份（不包括庫存股份）從上月的729,847,259股增加至729,989,776股，增加了142,517股。該增加主要源於首次公開發售後股份獎勵計劃的執行，導致新股數目增加。此外，報告還提到，公司的股份期權計劃在本月內發生了變動，包括股份期權的行使、註銷和失效。李安康博士以聯席公司秘書的身份確認，所有證券發行或庫存股份的出售或轉讓均已獲得董事會正式授權批准，並遵守所有適用的上市規則、法律及其他監管規定。
腾盛博药-B（02137.HK）於2024年7月3日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年6月30日的公司股份變動情況。報告顯示，公司的法定/註冊股本維持不變，為1,200,000,000股普通股，每股面值0.000005美元，總額6,000美元。同時，已發行股份（不包括庫存股份）從上月的729,847,259股增加至729,989,776股，增加了142,517股。該增加主要源於首次公開發售後股份獎勵計劃的執行，導致新股數目增加。此外，報告還提到，公司的股份期權計劃在本月內發生了變動，包括股份期權的行使、註銷和失效。李安康博士以聯席公司秘書的身份確認，所有證券發行或庫存股份的出售或轉讓均已獲得董事會正式授權批准，並遵守所有適用的上市規則、法律及其他監管規定。
On July 3, 2024, Tengshengbo Medicine - B (02137.HK) submitted the latest monthly report on securities changes to the Hong Kong Exchanges and Clearing Limited, reporting changes in the company's shareholding as of June 30, 2024. The report shows that the company's legal/registered capital remains unchanged at 1,200,000,000 shares of common stock, with a face value of 0.000005 US dollars per share, totaling 6,000 US dollars. At the same time, the issued shares (excluding treasury shares) increased from 729,847,259 shares last month to 729,989,776 shares, an increase of 142,517 shares. The increase was mainly due to the execution of the stock incentive plan after the initial public offering, leading to an increase in the number of new shares. In addition, the report also mentioned that the company's...Show More
On July 3, 2024, Tengshengbo Medicine - B (02137.HK) submitted the latest monthly report on securities changes to the Hong Kong Exchanges and Clearing Limited, reporting changes in the company's shareholding as of June 30, 2024. The report shows that the company's legal/registered capital remains unchanged at 1,200,000,000 shares of common stock, with a face value of 0.000005 US dollars per share, totaling 6,000 US dollars. At the same time, the issued shares (excluding treasury shares) increased from 729,847,259 shares last month to 729,989,776 shares, an increase of 142,517 shares. The increase was mainly due to the execution of the stock incentive plan after the initial public offering, leading to an increase in the number of new shares. In addition, the report also mentioned that the company's share option plan underwent changes this month, including the exercise, cancellation, and expiration of share options. Dr. Li An-kang confirmed as joint company secretary that all securities issuances or sales/transfers of treasury shares have been formally authorized and approved by the board of directors and comply with all applicable listing rules, laws and other regulatory requirements.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more